MSP Recovery (NASDAQ:MSPR) vs. MDxHealth (NASDAQ:MDXH) Head-To-Head Comparison

MDxHealth (NASDAQ:MDXH) and MSP Recovery (NASDAQ:MSPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Insider and Institutional Ownership

3.8% of MSP Recovery shares are held by institutional investors. 1.7% of MDxHealth shares are held by insiders. Comparatively, 50.5% of MSP Recovery shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

MDxHealth has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, MSP Recovery has a beta of -2.31, meaning that its stock price is 331% less volatile than the S&P 500.

Profitability

This table compares MDxHealth and MSP Recovery’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-29.90%	N/A	-22.51%
MSP Recovery	-7,328.48%	-326.80%	-81.27%

Analyst Recommendations

This is a breakdown of recent ratings for MDxHealth and MSP Recovery, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1	1	3	0	2.40
MSP Recovery	1	0	0	0	1.00

MDxHealth currently has a consensus price target of $3.50, indicating a potential upside of 739.93%. Given MDxHealth’s stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than MSP Recovery.

Earnings & Valuation

This table compares MDxHealth and MSP Recovery”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88 million	0.19	-$33.52 million	($0.65)	-0.64
MSP Recovery	$9.81 million	0.01	-$360.50 million	($572.83)	-0.00

MDxHealth has higher revenue and earnings than MSP Recovery. MDxHealth is trading at a lower price-to-earnings ratio than MSP Recovery, indicating that it is currently the more affordable of the two stocks.

Summary

MDxHealth beats MSP Recovery on 11 of the 14 factors compared between the two stocks.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About MSP Recovery

MSP Recovery, Inc. engages in the development of healthcare recoveries and data analytics software. It also focuses on the identification and recoveries of improper payments made by Medicare, Medicaid, and commercial insurance spaces using data and analytics. The company was founded by John H. Ruiz, Frank C. Quesada, and Diana Diaz on July 8, 2014 and is headquartered in Miami, FL.